This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessReview
Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy
by
Dong Oh Moon
Dong Oh Moon
Department of Biology Education, Daegu University, 201, Daegudae-ro, Gyeongsan-si 38453, Gyeongsangbuk-do, Republic of Korea
Cancers 2024, 16(17), 2958; https://doi.org/10.3390/cancers16172958 (registering DOI)
Submission received: 6 July 2024
/
Revised: 18 August 2024
/
Accepted: 22 August 2024
/
Published: 24 August 2024
Simple Summary
This review focuses on the current advancements in the development of inhibitors and the application of kinesin family member 20A (KIF20A) as a cancer immunotherapy target. KIF20A, a mitotic kinesin overexpressed in various cancers, plays a pivotal role in cell division and is increasingly recognized as a crucial factor in tumor progression and a potential target for novel cancer treatments.
Abstract
The analysis begins with a detailed examination of the gene expression and protein structure of KIF20A, highlighting its interaction with critical cellular components that influence key processes such as Golgi membrane transport and mitotic spindle assembly. The primary focus is on the development of specific KIF20A inhibitors, detailing their roles and the challenges encountered in enhancing their efficacy, such as achieving specificity, overcoming tumor resistance, and optimizing delivery systems. Additionally, it delves into the prognostic value of KIF20A across multiple cancer types, emphasizing its role as a novel tumor-associated antigen, which lays the groundwork for the development of targeted peptide vaccines. The therapeutic efficacy of these vaccines as demonstrated in recent clinical trials is discussed. Future directions are proposed, including the integration of precision medicine strategies to personalize treatments and the use of combination therapies to improve outcomes. By concentrating on the significant potential of KIF20A as both a direct target for inhibitors and an antigen in cancer vaccines, this review sets a foundation for future research aimed at harnessing KIF20A for effective cancer treatment.
Share and Cite
MDPI and ACS Style
Moon, D.O.
Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy. Cancers 2024, 16, 2958.
https://doi.org/10.3390/cancers16172958
AMA Style
Moon DO.
Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy. Cancers. 2024; 16(17):2958.
https://doi.org/10.3390/cancers16172958
Chicago/Turabian Style
Moon, Dong Oh.
2024. "Advancing Cancer Therapy: The Role of KIF20A as a Target for Inhibitor Development and Immunotherapy" Cancers 16, no. 17: 2958.
https://doi.org/10.3390/cancers16172958
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.